telavancin (vibativ) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
TELAVANCIN (VIBATIV®) is a lipoglycopeptide antibacterial that is a synthetic derivative of vancomycin. It exerts concentration-dependent, bactericidal activity against Gram-positive organisms in vitro. TELAVANCIN (VIBATIV®) inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. It also binds to the bacterial membrane and disrupts membrane barrier function. TELAVANCIN (VIBATIV®) is indicated for the treatment of adult patients with complicated skin and skin structure infections caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), or Enterococcus faecalis (vancomycin-susceptible isolates only). It is also indicated for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Staphylococcus aureus (both methicillin-susceptible and -resistant isolates). It should be reserved for use when alternative treatments are not suitable.   NCATS

Chemistry

  • SMILES: CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc3c4Oc5ccc(cc5Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@H]6C(=O)N[C@H]7C(=O)N[C@@H]([C@H](O)c8ccc(Oc3cc6c4)c(Cl)c8)C(=O)N[C@H](C(=O)O)c9cc(O)c(CNCP(=O)(O)O)c(O)c9c%10cc7ccc%10O)O[C@@H](C)[C@H]1O
  • InChIKey: ONUMZHGUFYIKPM-MXNFEBESSA-N
  • Mol. Mass: 1755.66
  • ALogP: Missing data
  • ChEMBL Molecules:
    telavancin  
    telavancin hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

arbelic | td6424 | td 6424 | td-6424 | telavancin | telavancina | télavancine | telavancin hcl | telavancin hydrochloride | telavancinum | vibativ

Organizations (9)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Pneumonia, Bacterial

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Abscess (Phase 2)

Bacteremia (Phase 3)

Burns (Phase 2)

Cellulitis (Phase 2)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Cystic Fibrosis (Phase 4)

Gram-Positive Bacterial Infections (Phase 4)

Healthy Volunteers (Phase 1)

Infections (Phase 2)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 4)

Pneumonia, Bacterial (Phase 3)

Staphylococcal Infections (Phase 3)

Ulcer (Phase 2)

Wound Infection (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue